Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 8-K (Current Report)
Date of Report: June 28, 2021
Subject: Clinical updates for Phase 1 trial of IDE397 in solid tumors with MTAP deletion and Phase 1/2 trial of darovasertib combinations in metastatic uveal melanoma (MUM).
Key Financial Metrics
This filing is a current report regarding clinical developments and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Contractual Financial Terms (IDE397/GSK Collaboration):
- Option Exercise Payment: $50,000,000 (contingent on GSK exercising its exclusive option).
- Future Development Milestones: Up to $465,000,000.
- Commercial Milestones: Up to $475,000,000.
- Profit Share: 50% of U.S. net profits.
- Royalties: Tiered royalties on global ex-U.S. net sales (high single digit to sub-teen double digit percentages).
- Cost Sharing (if option exercised): IDEAYA responsible for 20%; GSK responsible for 80%.
Material Changes and Clinical Updates
IDE397 (MTAP Deletion Solid Tumors)
- Progress: Enrolling patients in the third cohort of the dose escalation portion of the Phase 1 trial.
- Safety: Generally well tolerated as of June 25, 2021. Only Grade 1 drug-related adverse events reported (constipation, nausea, fatigue). No serious adverse events, myelosuppression, or liver enzyme changes reported.
- Pharmacodynamics (PD): Met criteria to initiate a tumor biopsy cohort. Maximal plasma SAM reduction from baseline was 68.9% (Cohort 1) and 88.0% (Cohort 2), exceeding the protocol threshold of approximately 60%.
- Partnership: Collaboration with Tempus Labs, Inc. to identify additional patients.
Darovasertib Combinations (Metastatic Uveal Melanoma)
- Darovasertib + Crizotinib: Initiated Phase 2 in June 2021. Confirmed partial response of 56.5% tumor reduction (deepest response observed to date in the trial).
- Darovasertib + Binimetinib: Confirmed partial response of 51.7% tumor reduction. Two confirmed partial responses out of nine evaluable patients (22%).
- Enrollment: As of June 22, 2021, 30 patients enrolled in the binimetinib arm and 15 in the crizotinib arm.
- Safety:
- Crizotinib Arm: Serious adverse events included syncope and hypotension (resolved with continued dosing). Managed via run-in dosing regimen.
- Binimetinib Arm: Serious adverse events included liver toxicity, nausea, vomiting, syncope, and fall.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- IDE397: Plans to obtain tumor biopsies to support a data package for GSK to review for option exercise. GSK option is exercisable within a certain period after data delivery.
- Darovasertib: Targeting a further clinical data update in the second half of 2021. Planning to seek FDA regulatory guidance on registration-enabling trial design in the first half of 2022.
Risks and Contingencies
- Forward-Looking Statements: Subject to risks including uncertainties in drug development, early-stage nature of programs, and potential delays in clinical trials.
- Regulatory Risk: FDA may not agree with the Company's interpretation of clinical data or trial designs.
- Commercial Risk: GSK may not exercise its option to develop and commercialize IDE397.
- Operational Risk: Challenges in manufacturing, intellectual property protection, and the impact of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the specific timeline for GSK's option exercise period for IDE397.
- Monitor the safety profile of darovasertib combinations, specifically regarding liver toxicity and hypotension/syncope, as enrollment continues.
- Confirm the timing of the FDA regulatory guidance meeting for darovasertib in H1 2022.
- Review the Company's most recent Form 10-Q (filed May 10, 2021) for actual cash burn rates and liquidity status, as this 8-K does not provide financial data.
- Assess the impact of the Tempus Labs collaboration on patient enrollment velocity for IDE397.